Rosuvastatin/telmisartan - Yuhan
Alternative Names: Duo Wellness; Duowell; Telmisartan/rosuvastatin; YH-16410; YMC 017Latest Information Update: 30 Oct 2021
At a glance
- Originator Yuhan
- Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
Most Recent Events
- 28 Oct 2016 Chemical structure information added
- 01 Jun 2014 Yuhan completes a phase III trial in Hyperlipidaemia & Hypertension in South Korea (NCT01914432)
- 30 Nov 2013 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO)